Libella Gene Therapeutics, LLC made the news last week for announcing a “pay-to-play” trial of its telomerase-based anti-aging gene therapy. What was shocking about the announcement was not that it was a “pay-to-play” trial, given that such trials have become all too common, but rather the price of enrollment: $1 million. Worse, the trial is being conducted in Colombia; the therapy doesn’t have the greatest preclinical justification; and it’s a phase 1 trial, which means it is only trial of safety, not efficacy. How can unethical and scientifically dubious trials like this be stopped?
Search: “"Stanislaw Burzynski"”
We found 388 results for your search.
Drs. Alberto Siller and Alberto Garcia are at it again at Clínica 0-19, peddling a dubious case series touting their DIPG treatment. Let’s just say that it does not demonstrate that their treatment is better than existing treatments; i.e., not very good.
Share this:
Ohio, you have a definite antivaccine problem in your statehouse. Unfortunately, Ohio is not alone. Antivaxers have outsized influence in too many state legislatures.
Share this:
Evee Clobes was a six month old who died due to SIDS. Unfortunately, antivaxers used the grief of her mother Caitlin to recruit her to their cause. It’s an all too common tactic, because antivaxers know that grieving mothers are their most potent messengers.
Share this:
Federal “right-to-try” legislation was passed and signed into law by President Trump over a year ago. Advocates promised that lots of terminally ill people who were dying then would be saved by having the right to “try” experimental therapies outside of the context of clinical trials. That has not happened. This should come as no surprise, because right-to-try was never about getting experimental drugs to dying patients. It was always about weakening the FDA and making money.
